id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1247-0007,FDA,FDA-2012-E-1247,Acknowledgment of Express Withdrawal of Application for Extension of Patent Term from U.S. Patent and Trademark Office to Covington & Burlington LLP,Other,Acknowledgement Letter/Receipt,2024-02-20T05:00:00Z,2024,2,2024-02-20T05:00:00Z,,2024-02-20T21:29:32Z,,0,0,09000064863cf16b
FDA-2012-E-1247-0006,FDA,FDA-2012-E-1247,Determination of Regulatory Review Period for Purposes of Patent Extension; BELVIQ,Other,Letter(s),2017-03-10T05:00:00Z,2017,3,2017-03-10T05:00:00Z,,2017-03-10T16:45:50Z,,0,0,090000648250021c
FDA-2012-E-1247-0005,FDA,FDA-2012-E-1247,"Determination of Regulatory Review Period for Purposes of Patent
Extension; BELVIQ",Notice,Determinations,2016-09-23T04:00:00Z,2016,9,2016-09-23T04:00:00Z,2016-11-23T04:59:59Z,2024-02-02T16:36:53Z,2016-22937,0,0,090000648225ae65
FDA-2012-E-1247-0004,FDA,FDA-2012-E-1247,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-18T04:00:00Z,2016,8,2016-08-18T04:00:00Z,,2016-08-18T13:11:04Z,,0,0,09000064821807bf
FDA-2012-E-1247-0003,FDA,FDA-2012-E-1247,FDA/CDER to U.S. Patent & Trademark Office – Letter,Other,Letter(s),2013-02-14T05:00:00Z,2013,2,2013-02-14T05:00:00Z,,2013-02-14T12:52:28Z,,0,0,09000064811f8981
FDA-2012-E-1247-0002,FDA,FDA-2012-E-1247,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-27T22:11:52Z,,0,0,090000648119ce81
FDA-2012-E-1247-0001,FDA,FDA-2012-E-1247,"Arena Pharmaceuticals Inc. (Finnegan, Henderson, Farabow, Garrett & Dunner, LLP) - Patent Extension Application",Other,Application,2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-27T22:11:52Z,,0,0,090000648119cde1